Physician profile
Samit Bhatheja
NPI 1871818385
$6,153.58
in general payments reported to CMS, 2019-2025
25 companies · $719 in 2025
The $719 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,354 · 2020: $396 · 2021: $680 · 2022: $579 · 2023: $631 · 2024: $794 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,010.83 | 2019-2025 | General - Brady, Lithovue Empower |
| Janssen Pharmaceuticals, INC | $617.64 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $529.12 | 2023-2025 | Lifevest |
| Abbott Laboratories | $427.65 | 2021-2025 | Mitraclip, Allure, Gallant |
| E.R. Squibb & Sons, L.L.C. | $341.18 | 2019-2023 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $298.84 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $237.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $220.82 | 2022-2025 | Verquvo |
| Abiomed | $201.59 | 2024 | Impella |
| Amgen INC. | $199.72 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.71 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $157.53 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $140.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $126.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $97.23 | 2022-2023 | Brilinta, Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $91.08 | 2020-2021 | |
| Chiesi USA, INC. | $76.69 | 2019-2025 | Kengreal |
| Lexicon Pharmaceuticals, INC. | $44.44 | 2023 | Inpefa |
| Medtronic, INC. | $42.18 | 2023 | Corevalve Evolut R |
| Inari Medical, INC. | $31.54 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cleerly, INC. | $18.70 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Regeneron Healthcare Solutions, INC. | $17.61 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.10 | 2023 | Opsumit, Uptravi |
| Cook Medical LLC | $15.00 | 2019 | |
| Astellas Pharma US INC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samit Bhatheja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.